SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes
NCT ID: NCT04816084
Last Updated: 2021-03-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
389 participants
INTERVENTIONAL
2020-11-05
2021-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Co-Sér: Serological Analysis and Viral Neutralization in People With a Documented COVID-19 Infection
NCT05000307
CoViD-19 Patient in Reims University Hospital in March to April 2020
NCT04553575
Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff
NCT04896788
Prospective Clinical and Virological Analysis of Healthcare Workers Diagnosed Positive for Covid-19.
NCT04858581
Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen
NCT04707833
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study was designed to determine, in a screening situation within the framework of university preventive medicine, the prevalence of positive anti-SARS-Cov 2 serology among the staff of the University of Reims Champagne-Ardenne. The serological tests chosen will allow systematic detection of anti-SARS-CoV-2 IgM and anti-SARS-Cov-2 IgG to assess the moment of potential contamination prior to resumption of occupational activity.
Type of study:
This is a prevalence study, a single-center cross-sectional study published on the human person.
Population:
Inclusion criteria: On a voluntary basis, the staff of the University of Reims Champagne Ardenne will be offered a serological blood test (1 dry tube of 7ml). The use of the collected data for research purposes will be explained to each requester, with signature of an informed consent. Only people over 18 will be included.
Non-inclusion criteria: Staff of the University of Reims Champagne Ardenne who have not requested to be tested. Duration of participation of subjects: 1/2 day time
Judgment criterion (s):
Main endpoint (in connection with the main objective): Prevalence of positive SARS-CoV-2 serology at the University of Reims Champagne-Ardenne.
Clinical investigation plan:
* Phase 1: Communication strategy An email will be sent to all the staff of the University of Reims Champagne Ardenne to offer them anti-SARS-Cov-2 serological tests, as part of a health research protocol. Before sampling, a questionnaire will be completed by the applicant.
* Phase 2: Analysis of the samples
* Phase 3: Transmission of results to Pr Frédéric Deschamps, head of SUMMPS at the University of Reims Champagne Ardenne
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Population
Voluntary people over 18 from the staff of the University of Reims Champagne Ardenne
Anti-SARS-CoV2 Serology
Diagnostic Test: Anti-SARS-CoV2 Serology A blood sample is collected by venipuncture at Day 0. The anti-SARS-CoV2 serological status is measured by with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays (EUROBIO®)
Other: Questionnaire
Data concerning personal exposure factors are collected in a questionnaire:
* Socio-demographic factors: sex, age,
* known risk-factor for Covid-19
* Professional factors: Employment (type, work time, location), protective measures put in place to reduce the risk of contamination
* Non-professional factors: Contact with infected individuals, carrying of protective equipment and compliance with barrier measures, transport and accomodation modalities during holidays
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-SARS-CoV2 Serology
Diagnostic Test: Anti-SARS-CoV2 Serology A blood sample is collected by venipuncture at Day 0. The anti-SARS-CoV2 serological status is measured by with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays (EUROBIO®)
Other: Questionnaire
Data concerning personal exposure factors are collected in a questionnaire:
* Socio-demographic factors: sex, age,
* known risk-factor for Covid-19
* Professional factors: Employment (type, work time, location), protective measures put in place to reduce the risk of contamination
* Non-professional factors: Contact with infected individuals, carrying of protective equipment and compliance with barrier measures, transport and accomodation modalities during holidays
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université de Reims Champagne-Ardenne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Delphine GIUSTI, MCU-PH
Role: PRINCIPAL_INVESTIGATOR
Université de Reims CHampahne-Ardenne - CHU de Reims
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Université de Reims Champagne-Ardenne
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-004-SERUR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.